Found 3 publications. Displayed publications from 1 to 3
Expand all publications       Show all as text (SweetDB notation)
1. (Article ID: 5213)
 
Shashkov AS, Kenyon JJ, Arbatsky NP, Shneider MM, Popova AV, Knirel YA, Hall RM
Genetics of biosynthesis and structure of the K53 capsular polysaccharide of Acinetobacter baumannii D23 made up of a disaccharide K unit
Microbiology 164(10) (2018) 1289-1292
 

TThe KL53 capsular polysaccharide (CPS) gene cluster of Acinetobacter baumannii D23 was sequenced, and includes a single gtr gene encoding the glycosyltransferase Gtr2, and the itrA1 gene for ItrA1 that is known to initiate CPS biosynthesis with d-QuiNAc4NAc. The K53 CPS was isolated and studied by one- and two-dimensional 1H and 13C nuclear magnetic resonance (NMR) spectroscopy before and after O-deacetylation. The disaccharide K unit of the CPS was established as →3)-α-d-GalpNAcA4Ac-(1→3)-β-d-QuipNAc4NAc-(1→, where GalNAcA and QuiNAc4NAc indicate 2-acetamido-2-deoxygalacturonic acid and 2,4-diacetamido-2,4,6-trideoxyglucose, respectively. This established the linkage formed by Gtr2. The degree of 4-O-acetylation of d-GalNAcA by Atr18, encoded at the KL53 locus, is ~55 %.

Acinetobacter baumannii, capsular polysaccharide, 2, 4-diacetamido-2, 4, 6-trideoxy-D-glucose, 2-acetamido-2-deoxy-D-galacturonic acid, K locus, KL53

The publication contains the following compound(s):
 

Expand this publication
2. (Article ID: 5500)
 
Singh JK, Adams FG, Brown MH
Diversity and Function of Capsular Polysaccharide in Acinetobacter baumannii
Frontiers in Microbiology 9 (2019) 3301
 

The Gram-negative opportunistic bacterium Acinetobacter baumannii is a significant cause of hospital-borne infections worldwide. Alarmingly, the rapid development of antimicrobial resistance coupled with the remarkable ability of isolates to persist on surfaces for extended periods of time has led to infiltration of A. baumannii into our healthcare environments. A major virulence determinant of A. baumannii is the presence of a capsule that surrounds the bacterial surface. This capsule is comprised of tightly packed repeating polysaccharide units which forms a barrier around the bacterial cell wall, providing protection from environmental pressures including desiccation and disinfection regimes as well as host immune responses such as serum complement. Additionally, capsule has been shown to confer resistance to a range of clinically relevant antimicrobial compounds. Distressingly, treatment options for A. baumannii infections are becoming increasingly limited, and the urgency to develop effective infection control strategies and therapies to combat infections is apparent. An increased understanding of the contribution of capsule to the pathobiology of A. baumannii is required to determine its feasibility as a target for new strategies to combat drug resistant infections. Significant variation in capsular polysaccharide structures between A. baumannii isolates has been identified, with over 100 distinct capsule types, incorporating a vast variety of sugars. This review examines the studies undertaken to elucidate capsule diversity and advance our understanding of the role of capsule in A. baumannii pathogenesis.

polysaccharide, Acinetobacter, Acinetobacter baumannii, capsule, virulence factor, persistence

The publication contains the following compound(s):
 

Expand this publication
3. (Article ID: 6211)
 
Del Bino L, Osterlid KE, Wu DY, Nonne F, Romano MR, Codée J, Adamo R
Synthetic Glycans to Improve Current Glycoconjugate Vaccines and Fight Antimicrobial Resistance
Chemical Reviews 122(20) (2022) 15672-15716
 

Antimicrobial resistance (AMR) is emerging as the next potential pandemic. Different microorganisms, including the bacteria Acinetobacter baumannii, Clostridioides difficile, Escherichia coli, Enterococcus faecium, Klebsiella pneumoniae, Neisseria gonorrhoeae, Pseudomonas aeruginosa, non-typhoidal Salmonella, and Staphylococcus aureus, and the fungus Candida auris, have been identified by the WHO and CDC as urgent or serious AMR threats. Others, such as group A and B Streptococci, are classified as concerning threats. Glycoconjugate vaccines have been demonstrated to be an efficacious and cost-effective measure to combat infections against Haemophilus influenzae, Neisseria meningitis, Streptococcus pneumoniae, and, more recently, Salmonella typhi. Recent times have seen enormous progress in methodologies for the assembly of complex glycans and glycoconjugates, with developments in synthetic, chemoenzymatic, and glycoengineering methodologies. This review analyzes the advancement of glycoconjugate vaccines based on synthetic carbohydrates to improve existing vaccines and identify novel candidates to combat AMR. Through this literature survey we built an overview of structure-immunogenicity relationships from available data and identify gaps and areas for further research to better exploit the peculiar role of carbohydrates as vaccine targets and create the next generation of synthetic carbohydrate-based vaccines.

carbohydrates, glycan, glycoconjugate vaccine

The publication contains the following compound(s):
 

Expand this publication

Resort publications by:

New query Export IDs Home Help

Execution: 1 sec